Device Trial Radar · NCT02453373
Helping Stroke Patients With ThermoSuit Cooling
Last checked: Nov 20, 2026Latest source record: Jun 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
14
Actual
Start
Jan 25, 2017
Primary completion
Jun 1, 2023
Study completion Jun 2, 2023
Sponsor
- Lead sponsor
- Life Recovery SystemsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tulane University School of Medicine; Geisinger Clinic
- First posted
- May 25, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to assess the feasibility of using the Life Recovery Systems ThermoSuit Device to induce therapeutic hypothermia (32-34°C) in victims of ischemic stroke. This feasibility clinical study will enroll a total of 30 patients with acute ischemic stroke at four clinical centers. Subjects will receive hypothermia plus conventional therapy (such as IV-tPA and/or neurothrombectomy therapies if indicated). Endpoints will include feasibility of cooling, adverse events, and neurological recovery in comparison with matched historical controls.
Conditions
- Stroke
- Brain Ischemia
Interventions
ThermoSuit Cooling InductionDevice
Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
Magnesium SulfateDrug
Magnesium sulfate will be administered intravenously as needed to control shivering
tPADrug
tPA will be administered intravenously if indicated
PropofolDrug
Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
EtomidateDrug
Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
NeurothrombectomyProcedure
If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility of cooling as indicated by percentage of patients cooled to target within 1 hour of start of coolingTime frame: 1 hour after start of cooling
5 more outcomes with a free account
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Tulane University
New Orleans, Louisiana
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.